SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Internet Computer (IC) is the world’s first blockchain that is capable of running at web speed at unrestrictive capacities. Built by the DFINITY Foundation, IC aims to recreate the web by supporting smart contract development at scale and changing the way people can interact using web services. Internet Computer aims to extend the public internet, so that it can be the world’s computing platform, in a decentralized manner. Internet Computer sets to revolutionalize the design of the crypto economy, with an aim to overhaul traditional software services.   The project was founded in October 2016 by Dominic WIllams and have raised a total of $121 million from investors such as Adreessen Horowitz, Polychain Capital, Multicoin Capital and such. On May 10, 2021, DFINITY launched the Internet Computer into the public domain, marking it a major milestone for ICP as it means the internet now functions as a decentralised global computer. This is marked by the release of all of the Internet Computer’s source code into the public domain, as well as ICP utility token that allows tens of thousands of community members to govern the Internet Computer network.  ICP is Internet Computer's native token. It plays three prominent roles:  1. Network Governance: Users that participate in the governance will be rewarded with ICPI 2. Production of Cycles for Compute: ICP can be converted into cycles where it is used as the transaction fee to access the network. Cycles are burned after used. 3. Rewarding Users: ICP is used as the rewards to incentivize users to participate in the network such as securing the network.

Internet Computer

ICP is trending due to renewed community excitement around its technology as a decentralized internet solution and potential to challenge centralized cloud services. Discussions highlight its unique architecture, interoperability with other blockchains, and recent developments like Caffeine AI, driving speculation about future growth and adoption. Some traders are drawing comparisons to ZCash's previous price movements, while others caution against shorting and emphasize long-term potential.

Eastman Kodak Co. engages in the provision of analog and digital innovations. It operates through the following segments: Traditional Printing, Digital Printing, Advanced Materials and Chemicals, and Brand. The Traditional Printing segment consists of Prepress Solutions, which includes Kodak's digital offset plate offerings and computer-to-plate imaging solutions. The Digital Printing segment contains Electrophotographic Printing Solutions, Prosper, Versamark and Software. The Advanced Materials and Chemicals segment consists of four lines of business: Industrial Film and Chemicals, Motion Picture, Advanced Materials and Functional Printing, and Kodak Services for Business (KSB). The Brand segment includes licensing of the Kodak brand to third parties. The company was founded by George Eastman in 1880 and is headquartered in Rochester, NY.

Eastman Kodak Co.

Eastman Kodak Co. is trending due to its ongoing transformation from a legacy print business into high-margin sectors like pharmaceuticals and advanced materials, with the community highlighting the imminent launch of its pharma division in 2025. Discussions also focus on the company's debt reduction plans using pension assets, potential trade policy tailwinds, and undervalued real estate holdings. Investors are closely watching for news and contracts related to Kodak's pharmaceutical ventures, with some speculating about partnerships and a potential meme stock resurgence.

The Filecoin network achieves staggering economies of scale by allowing anyone worldwide to participate as storage providers. It also makes storage resemble a commodity or utility by decoupling hard-drive space from additional services. On this robust global market the price of storage will be driven by supply and demand, not corporate pricing departments, and miners will compete on factors like reputation for reliability as well as price.

Filecoin

Filecoin is trending as investors discuss its potential in decentralized data storage, especially in light of AI and Web3 projects. Community members are actively comparing it to other cryptocurrencies like ZEC and DASH, speculating on price targets, and highlighting its real-world utility, such as competing with Amazon AWS. The conversation also mentions Filecoin's use cases with Solana and NASA.

Sei is a high-performance Layer 1 blockchain that scales the EVM with parallelized execution, enabling faster transactions, low fees, and seamless smart contract deployment. Sei removes traditional blockchain bottlenecks while maintaining full Ethereum compatibility. The upcoming Giga upgrade will deliver 50x improvements in EVM throughput, optimizing execution, consensus, and storage to push blockchain performance to web2 levels.

SEI is gaining attention as community members discuss its potential, comparing it to other popular chains like Solana and SUI. The recent listing on Robinhood is a catalyst, with some seeing it as a signal for potential growth, while others express concern about its historical impact on coin performance. Community discussions include speculation on future price targets and debate around whether it's a good entry point.

Aventus Network

Aventus Network ($AVT) is trending as community members highlight its strong technology, recent company updates (especially around Aventus Cloud), partnerships with Vodafone, Heathrow airport, and Polkadot, and potential for a breakout. Traders are watching for increased volume, believing that $AVT is undervalued with significant upside potential due to its small circulating supply and Polkadot integration. Some compare it to other low cap coins like $MUSE, anticipating a potential pump.

P8BCI Is the CCM Creator Capital Markets Creator token created by Nick Wray, intended to form a community for talking about his journey with ALS, his experiences with Telepathy BCI experiments, as well as his experiences and journey through the Solana blockchain, and cryptocurrency world of Web 3. In addition to this, prior to his progression of ALS Nick was an avid drummer, a creative, and an enjoyer of philosophical discussion - and enabled now by his BCI explores creating, and in addition to sharing his story, interacting with the community forming around his experiences.

Telepath8

Telepath8 ($P8BCI) is trending amid community excitement over its developer's purported connection to Neuralink and Elon Musk. Discussions center on the project's innovative development process and potential synergies with neurotechnology, fueling bullish sentiment.

Crane Harbor Acquisition Corp. operates as a blank check company. It was formed for the purpose of effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization, or similar business combination with one or more businesses. The company was founded on January 2, 2025 and is headquartered in Philadelphia, PA.

Crane Harbor Acquisition Corp. - Ordinary Shares - Class A

Chardan Healthcare

Chardan Healthcare (CHAC) is trending due to its merger with Xanadu, a quantum computing firm, generating excitement within the community. Discussions revolve around Xanadu's technology, including its PennyLane software and potential partnerships, as well as comparisons to other quantum computing companies. Some are also looking into CHAC's rights offerings and their relationship to the stock.

Ambiq Micro, Inc. engages in the provision of ultra-low power semiconductor solutions designed to address the significant power consumption challenges of general purpose and AI computing. It operates through the following geographical segments: China, Taiwan, Singapore, and Rest of the World. The company was founded by Scott Hanson, Dennis Sylvester, and David Blaauw on January 20, 2010 and is headquartered in Austin, TX.

Ambiq Micro Inc.

Ambiq Micro, Inc.

Ambiq Micro ($AMBQ) is trending as the community discusses its potential in the AI chip space, particularly its focus on ultra-low power solutions and key partnerships. Despite recent earnings, sentiment is mixed, with some expressing frustration and others hoping for a buyout or strategic move to unlock value. Bullish investors point to the company's innovative technology and potential for significant growth in the edge AI market, drawing comparisons to other successful chip companies.

London-based Quant Network is set to revolutionise blockchain technology with the development of their blockchain operating system Overledger. The experienced team are determined to fulfil the original vision of the internet by creating an open trusted network for people, machines, and data to operate securely and safely.  Overledger -the first interoperable blockchain operating system that facilitates internet-scale development of decentralised, multi-chain applications. Overledger has the ability to unlock and distribute value and applications across current and future blockchains. It is an agnostic platform that connects the world's networks to blockchains and ensures you're not limited to any single a vendor or technology. Overledger is the only platform that facilitates the development of internet-scales development of decentralised, multi-chain applications.

Quant

Quant is trending as the community discusses its potential role in connecting blockchains and traditional systems, particularly with updates around Overledger and Quant Flow. Some traders are eyeing a breakout above key resistance levels, while others speculate on staking opportunities and long-term growth prospects. The conversation also includes its relation to ISO20022 compliance.

Lowe's Companies, Inc. engages in the retail sale of home improvement products. The firm offers products for maintenance, repair, remodeling, home decorating, and property maintenance. It also provides home improvement products in the following categories: appliances, seasonal & outdoor living, lumber, lawn & garden, kitchens & bath, hardware, building materials, millwork, paint, rough plumbing, tools, electrical, flooring, and décor. The company was founded in 1946 and is headquartered in Mooresville, NC.

Lowe`s Cos., Inc.

Lowe's Companies, Inc.

Lowe's is trending as community members discuss analyst upgrades and the company's Q3 earnings report, which beat expectations despite a challenging DIY market. The community is weighing the impact of a strong Pro segment and potential benefits from future interest rate cuts, while also noting that the stock dipped despite the positive news. Some see a buying opportunity, while others are taking profits and considering options strategies.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Taysha Gene Therapies (NASDAQ:TSHA) Downgraded by Wall Street Zen to Sell

Wall Street Zen downgraded Taysha Gene Therapies from a "hold" rating to a "sell" rating in a research report on Saturday...

Taysha Gene Therapies (NASDAQ:TSHA) Stock Price Down 8.5% - Here's What Happened

Taysha Gene Therapies (NASDAQ:TSHA) Stock Price Down 8.5% - Here's What Happened...

Taysha Gene Therapies' (TSHA) "Buy" Rating Reiterated at Chardan Capital

Chardan Capital restated a "buy" rating and issued a $12.00 price target on shares of Taysha Gene Therapies in a research note on Wednesday...

Citizens Jmp Boosts Taysha Gene Therapies (NASDAQ:TSHA) Price Target to $8.00

Citizens Jmp boosted their price target on Taysha Gene Therapies from $6.00 to $8.00 and gave the stock a "market outperform" rating in a report on Wednesday...

Personalis (PSNL) Moves 20.5% Higher: Will This Strength Last?

Personalis (PSNL) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.

Shares of Taysha Gene Therapies ended at their highest level in over three years on Thursday after a wave of bullish analyst upgrades followed the U.S. Food and Drug Administration’s (FDA) Breakthrough Therapy designation for its Rett syndrome gene therapy candidate, TSHA-102.The stock soared 53.5% on Thursday, extending gains by another 2% in after-hours trading.Baird raised its price target on Taysha to $12 from $7 and reiterated an 'Outperform' rating. Analyst Jack Allen said the firm is “encouraged” that Taysha reached alignment with the FDA on the 15-patient pivotal study for TSHA-102, calling the breakthrough therapy designation “another encouraging sign” for the company’s regulatory and clinical progress.H.C. Wainwright said Taysha has added roughly $1.2 billion to its valuation since receiving Breakthrough Therapy designation and aligning with the FDA on a six-month interim Biologics License Application (BLA) filing plan.&nbsp;The firm noted that while the accelerated pathway appears faster “on paper,” Rett specialists it surveyed said the six-month interim analysis was “directionally useful but insufficient on its own to be considered definitive for projecting patient outcomes.”&nbsp;The analysts added that Taysha’s pathway “looks faster on paper, but may not translate into a true lead.” In comparison, the firm said Neurogene, whose FDA-cleared 12-month design “mitigates the risk of approvability,” looks “deeply undervalued.” H.C. Wainwright reiterated its Buy rating and $45 price target on Neurogene, citing its durability focus and caregiver appeal.Needham analyst Gil Blum also raised the price target on Taysha to $10 from $8, keeping a 'Buy' rating. Blum told investors that the FDA’s feedback on Taysha’s registrational study design “checked off a wishlist of features,” including the agency’s willingness to allow for a six-month interim filing. The analyst said these developments “derisk” the TSHA-102 program and position it “well ahead of NGNE-401.”The FDA’s Breakthrough Therapy designation was based on data from 12 patients in an early-to mid-stage trial of TSHA-102 and allows for an expedited review process.&nbsp;Taysha has finalized alignment with the agency on the design of its registrational study, which will test a single intrathecal administration of high-dose TSHA-102 in 15 female patients aged 6 to under 22 years. The company plans to begin enrollment in the fourth quarter of 2025.On Stocktwits, retail sentiment for Taysha was ‘extremely bullish’ amid a 34,800% surge in 24-hour message volume.One retail trader said they expect institutional investors to accumulate Taysha shares around the $5 mark, predicting a quick move toward $6.&nbsp;<stembedurl>https://stocktwits.com/warren5677/message/630844528</stembedurl>Another user said they had exited their position at $4.85, citing the company’s high debt levels and booking an 8% profit.<stembedurl>https://stocktwits.com/intrader/message/630837982</stembedurl><a href="https://stocktwits.com/symbol/TSHA">Taysha’s stock</a> has nearly tripled so far in 2025.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Taysha’s stock (TSHA) has nearly tripled so far in 2025. (Photo credit: Getty Images)

Taysha Gene Therapies Stock Soars To 3-Year High After FDA Boost — Wall Street Calls Rett Drug ‘Derisked’ And Ahead Of Rivals

Taysha shares jumped after analysts at Baird, H.C. Wainwright, and Needham turned bullish, citing FDA alignment and an expedited approval path for its Rett syndrome therapy.

Equity

Shares of Taysha Gene Therapies, Inc. (TSHA) rallied 49% by Thursday morning after the U.S. Food and Drug Administration granted Breakthrough Therapy designation to its gene therapy TSHA-102 for the treatment of Rett syndrome.Rett syndrome is a rare genetic neurological and developmental disorder that affects the way the brain develops. The disorder, which primarily occurs in females, is characterized by loss of communication and hand function, slowing and/or regression of development, motor and respiratory impairment, seizures, intellectual disabilities, and shortened life expectancy.<a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://ir.tayshagtx.com/news-releases/news-release-details/taysha-gene-therapies-announces-fda-breakthrough-therapy">According</a> to Taysha, there are currently no approved disease-modifying therapies that treat the genetic root cause of the disease, which affects between 15,000 and 20,000 patients in the U.S., the EU, and the U.K.The FDA on Thursday granted Taysha’s TSHA-102 Breakthrough Therapy designation. It is intended to expedite the development and regulatory review of an investigational therapy intended to treat a serious condition. The designation follows the agency’s review of available clinical data from the 12 patients treated in a part of its early-to mid-stage trials.On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/TSHA">TSHA stock</a> jumped from ‘bearish’ to ‘extremely bullish’ territory over the past 24 hours, while message volume improved from ‘normal’ to ‘extremely high’ levels.<figure class="image"><img style="aspect-ratio:573/63;" src="https://news.stocktwits-cdn.com/Screenshot_2025_10_02_at_11_39_41_AM_png_8ca9f60f70.webp" alt="TSHA's Sentiment Meter and Message Volume as of 11:39 a.m. ET on Oct. 02, 2025 | Source: Stocktwits" width="573" height="63"><figcaption>TSHA's Sentiment Meter and Message Volume as of 11:39 a.m. ET on Oct. 02, 2025 | Source: Stocktwits</figcaption></figure>Taysha also said on Thursday that it has finalized alignment with the FDA on the protocol for the trial intended to support its application for approval of TSHA-102. The company is now on track to begin patient enrollment in the trial in the fourth quarter of 2025. In the trial, a single intrathecal administration of high-dose TSHA-102 will be evaluated in 15 females between the ages of six and below 22 years with Rett syndrome.Following the news, Needham analyst Gil Blum raised the firm's price target on Taysha Gene Therapies to $10 from $8 while keeping a ‘Buy’ rating on the shares. Needham views the developments as "derisking" for TSHA-102, putting the program well ahead of Neurogene’s gene therapy NGN-401, which is also being evaluated for Rett syndrome.TSHA stock has risen 174% this year and by about 131% over the past 12 months.&nbsp;Read also:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/tesla-reports-7-percent-rise-in-q3-deliveries/chCrXlDR3Ow">Tesla’s Q3 Deliveries Hit Quarterly Record, Rise 7% To Exceed Analyst Estimates</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Rising stock market chart on a trading board background.

Taysha Gene Therapies Stock Soars After FDA Grants Breakthrough Therapy Designation To Gene Therapy

Taysha also announced that it has finalized alignment with the FDA on the protocol for the trial intended to support its application for approval of TSHA-102.

Taysha Gene Therapies, Inc. (TSHA) Reports Q2 Loss, Beats Revenue Estimates

Taysha Gene Therapies (TSHA) delivered earnings and revenue surprises of -28.57% and +15.73%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

Amphastar Pharmaceuticals (AMPH) Q2 Earnings and Revenues Beat Estimates

Amphastar (AMPH) delivered earnings and revenue surprises of +19.72% and +2.69%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

Will Taysha Gene Therapies, Inc. (TSHA) Report Negative Q2 Earnings? What You Should Know

Taysha Gene Therapies (TSHA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Taysha Gene Therapies, Inc. is a clinical-stage biotechnology company, which engages in the development and commercialization of adeno-associated viruses (AAV) based gene therapies for the treatment of monogenic diseases of the central nervous system. It also develops multiple gene therapy platforms which include AAV9 Discovery, Novel Capsid, and AAV Redosing. The company was founded by Steven Gray, Berge Minassian, and R. A. Session II in 2019 and is headquartered in Dallas, TX.

Taysha Gene Therapies Inc

$ASTS

$RKLB

$BBAI

$NBIS

Which earnings release are you most excited for the week of Nov. 10? 
 
Drop a comment for others.

TSHA
Taysha Gene Therapies Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Poll

Latest TSHA News

TSHATaysha Gene Therapies Inc